{"protocolSection":{"identificationModule":{"nctId":"NCT01606995","orgStudyIdInfo":{"id":"15914"},"secondaryIdInfos":[{"id":"XA1101","type":"OTHER","domain":"Company internal"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation","officialTitle":"Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation","acronym":"XANTUS"},"statusModule":{"statusVerifiedDate":"2022-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-06-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2015-03-06","type":"ACTUAL"},"completionDateStruct":{"date":"2015-03-31","type":"ACTUAL"},"studyFirstSubmitDate":"2012-05-24","studyFirstSubmitQcDate":"2012-05-25","studyFirstPostDateStruct":{"date":"2012-05-28","type":"ESTIMATED"},"lastUpdateSubmitDate":"2022-08-01","lastUpdatePostDateStruct":{"date":"2022-08-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Stroke","Embolism","Atrial fibrillation"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":6784,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator","armGroupLabels":["Group 1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Adjudicated major bleeding events","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy"},{"measure":"Safety variables will be summarized using descriptive statistics based on adverse events collection","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy"}],"secondaryOutcomes":[{"measure":"All cause mortality","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy"},{"measure":"Adjudicated symptomatic thromboembolic events","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy"},{"measure":"Persistence with rivaroxaban treatment: Reasons for any switch from or interruption of rivaroxaban treatment","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Multiple Locations","country":"Austria"},{"city":"Multiple Locations","country":"Belgium"},{"city":"Multiple Locations","country":"Canada"},{"city":"Multiple Locations","country":"Czechia"},{"city":"Multiple Locations","country":"Denmark"},{"city":"Multiple Locations","country":"France"},{"city":"Multiple Locations","country":"Germany"},{"city":"Multiple Locations","country":"Hungary"},{"city":"Multiple Locations","country":"Ireland"},{"city":"Multiple Locations","country":"Israel"},{"city":"Multiple Locations","country":"Moldova, Republic of"},{"city":"Multiple Locations","country":"Netherlands"},{"city":"Multiple Locations","country":"Norway"},{"city":"Multiple Locations","country":"Poland"},{"city":"Multiple Locations","country":"Portugal"},{"city":"Multiple Locations","country":"Russian Federation"},{"city":"Multiple Locations","country":"Slovakia"},{"city":"Multiple Locations","country":"Slovenia"},{"city":"Multiple Locations","country":"Sweden"},{"city":"Multiple Locations","country":"Ukraine"},{"city":"Multiple Locations","country":"United Kingdom"}]},"referencesModule":{"references":[{"pmid":"32079476","type":"DERIVED","citation":"Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, van Eickels M, Turpie AGG, Camm AJ; XANTUS Investigators*. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. J Am Heart Assoc. 2020 Mar 3;9(5):e009530. doi: 10.1161/JAHA.118.009530. Epub 2020 Feb 21."},{"pmid":"30423165","type":"DERIVED","citation":"Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):70-79. doi: 10.1093/ehjcvp/pvy041."},{"pmid":"29976287","type":"DERIVED","citation":"Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators. Global Prospective Safety Analysis of Rivaroxaban. J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058."},{"pmid":"29016755","type":"DERIVED","citation":"Camm AJ, Turpie AGG, Hess S, Amarenco P, Lambelet M, Haas S, van Eickels M, Kirchhof P; XANTUS Investigators. Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127."},{"pmid":"26330425","type":"DERIVED","citation":"Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG; XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016 Apr 7;37(14):1145-53. doi: 10.1093/eurheartj/ehv466. Epub 2015 Sep 1."},{"pmid":"25083135","type":"DERIVED","citation":"Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, van Eickels M, Turpie AG. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag. 2014 Jul 17;10:425-34. doi: 10.2147/VHRM.S63298. eCollection 2014."}],"seeAlsoLinks":[{"label":"Click here to find information for studies related to Bayer products. To find this study enter the NCT number or Bayer Study ID in the search field.","url":"http://clinicaltrials.bayer.com/"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Czech Republic","Greece","Italy","Spain"]},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M7474","name":"Embolism","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}